Mirko Jevto Stanetic

Prof. Dr. Mirko Jevto Stanetic

Lung Clinic, University clinical center of Republika Srpska, Banja Luka, Srpska, Republika, Bosnia and Herzegovina
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2011
Verified
Journal Article
Closed access
Pedja KovacevicPedja Kovacevic
Pedja Kovacevic
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
ZRZvezdana Rajkovaca
Zvezdana Rajkovaca
FMF Joachim Meyer
F Joachim Meyer
MVMarija Vukoja
Marija Vukoja

29 April 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
TKTijana Kovacevic
Tijana Kovacevic
SKSandra Vezmar Kovacevic
Sandra Vezmar Kovacevic
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
Pedja KovacevicPedja Kovacevic
Pedja Kovacevic
BMBranislava Miljkovic
Branislava Miljkovic
Background: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients.

21 November 2021 in Acta Medica Academica
Verified
Journal Article
Open access
PDF file
KSKosana Stanetić
Kosana Stanetić
BSBojan Stanetic
Bojan Stanetic
VPVerica Petrović
Verica Petrović
BMBrankica Marković
Brankica Marković
VKVesna Kević
Vesna Kević
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
Objective. The aim of our study was to investigate the predictors of morbidity (age, gender, smoking habits, obesity and the presence of chronic diseases) and COVID-19 outcomes. Subjects and Methods. The research was an observational descriptive study, conducted at The Family Medicine Education Center, The Primary Health Care Center, Banja Luka, in the period from 26th June to 31st December 2020. During the research period, seven family medicine teams followed their patients with COVID-19, and recorded possible predictors for morbidity and their influence on the disease outcome. Results. The study included 934 patients, 46.90% of whom were male. The majority of subjects were non-smokers and overweight. Diabetes was found in 5.57% patients, hypertension in 29.44%, chronic respiratory diseases in 5.25%, cancer in 4.39% patients. In the observed sample, 29.23% subjects contracted pneumonia, 18.52% were hospitalized, while 19 (2.03%) patients with severe clinical features had a fatal outcome. Multivariable regression analysis showed a high risk of pneumonia in male patients [OR=2.45, 95% CI (1.73-3.46)], elderly [OR= 1.07, 95% CI (1.06-1.09)] and obese patients with Body Mass Index ≥30.0 kg/m2 [OR=2.55, 95% CI (1.73-3.77)]. Male gender [OR=2.19, 95% CI (1.11-4.31)], older age [OR=1.08, 95% CI (1.05-1.11)] and hypertension [OR=2.51, 95% CI (1.06-5.91)] were the most important predictors for the development of severe clinical features in COVID 19. The statistically significant predictors of mortality were male gender [OR=7.16, 95% CI (1.56-32.86)] and older age [OR=1.12, 95% CI (1.06-1.18]. Conclusion. Being familiar with the predictors of morbidity and poor outcome in COVID-19 is helpful for carrying out preventive measures, early diagnosis and treatment of risk groups of patients.

1 September 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LLLora Novakovic Lackovic
Lora Novakovic Lackovic
MTMilica Srecic Tomic
Milica Srecic Tomic
MNMarko Novakovic
Marko Novakovic
MTMirko Turic
Mirko Turic
AKAleksandra Kajkut
Aleksandra Kajkut
RGRanko Glamocak
Ranko Glamocak
Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) without targetable mutations. This study aimed to assess real-world outcomes of pembrolizumab monotherapy in patients with high PD-L1 expression (≥50%) and compare them with results from the KEYNOTE-024 clinical trial.Methods: This retrospective study included patients with advanced or metastatic NSCLC treated with pembrolizumab as first-line therapy at the Clinic for Pulmonary Diseases, University Clinical Center of Republika Srpska, between January 2018 and December 2022. Clinical and pathological data were collected from medical records and analyzed using descriptive and inferential statistical methods.Results: The cohort included 46 patients with a median age of 64 years; 56.5% were aged ≥65, 73.9% were male, 76% were smokers, and 72% had an ECOG performance status of 1. Adenocarcinoma (AC) and squamous cell carcinoma (SCC) were diagnosed in 50 and 46% of cases, respectively, while 70% had metastatic disease and 15% had brain metastases. The two-year objective response rate (ORR) was 72.2%, lower than the 85.7% reported in KEYNOTE-024, possibly due to differences in PD-L1 assay (SP263 vs. 22C3) and patient selection. Despite this, the median overall survival (OS) was 36 months—higher than in the trial. One-, two-, and three-year survival rates were 57.9, 53.5, and 42.8%, respectively.Conclusion: Our findings confirm the clinical benefit of pembrolizumab in a real-world setting, despite lower ORR compared to clinical trial data. However, the prognosis remains guarded due to the advanced stage and comorbidities of the population. Further investigation is warranted to optimize patient selection and treatment strategies.

1 January 2012 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
ZRZvezdana Rajkovaca
Zvezdana Rajkovaca
Pedja KovacevicPedja Kovacevic
Pedja Kovacevic
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
SRSinisa Ristic
Sinisa Ristic
Background/Aim. The most sensitive indicators for detecting recurrence of well-differentiated thyroid cancer (DTC) are 131I whole body scintigraphy (WBS) and measurement of serum thyroglobulin (Tg). In order to perform it, it is necessary to raise the level of endogenous tiroidstimulating hormon (TSH), which can be achieved by Lthyroxine withdrawal for 3-5 weeks or administration of recombinant human thyrotropin (rhTSH) without requiring the discontinuation of thyroid hormone therapy. The aim of this study was to assess the effect of rhTSH using in comparison to the traditional thyroid hormone withdrawal in the follow-up of patients with DTC. Methods. This retrospective study included 44 patients, mean age 48.8 years, with DTC divided into 2 groups. The group I consisted of patients (n = 31) in which the analysis in the follow-up (WBS with 131I, TSH, Tg and antiTgAt) made in the hypothyroid state, and group II patients (n = 13) in which they made after the administration of rhTSH. The presence of 13 symptoms and signs of hypothyroidism was investigated on the day of giving 131I. Quality of life was evaluated using a modified form: the quality of life scale (SF-36) completed on the day of giving 131I. Results. In both groups, serum TSH reached a very good stimulation level, but significantly higher in the group II (group I 30.3-101.5 ?lU/mL, group II 68.6-192.0 ?lU/mL, p < 0.05). In both groups, TSHstimulated Tg was higher (group I 0.1-546.0 ng/mL, group II 0.1-7517 ng/mL) comapred to value during the Lthyroxine therapy (group I 0.1-495.0 ng/mL, group II 0.1- 2785 ng/mL). There was no difference in technical quality of WBS obtained from both groups. The patients in the group I had attended 8-13 symptoms of hypothyroidism, while patients in group II did not have symptoms of hypothyroidism. The patients after application of rhTSH, showed statistically significantly better quality of life as compared with those who showed to have L-thyroxine withdrawal, (74-91 points vs 43-62 points; p < 0.05). The rhTSH was well tolerated, with nausea occurring in only one patient. Conclusion. Administration of rhTSH in the follow- up of patients with DTC prevents the debilitating effects of hypothyroidism contributing to the maintenance of metabolic homeostasis of the organism and preserves the quality of life. RhTSH is safe, effective and easy to use, but is still an expensive product in our country.

11 June 2018 in Respiratio
Verified
Journal Article
Closed access
MLMedicinski Fakultet Univerzitet U Banjoj Luci
Medicinski Fakultet Univerzitet U Banjoj Luci
KSKosana Stanetić
Kosana Stanetić
SJSanja Janković
Sanja Janković
BLBanja Luka Dom Zdravlja Banja Luka
Banja Luka Dom Zdravlja Banja Luka
Mirko Jevto StaneticMirko Jevto Stanetic
Mirko Jevto Stanetic
SSSuzana Savić
Suzana Savić